English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background/Aims In patients starting steroids for giant cell arteritis (GCA), to evaluate adherence to BSR guideline: HbA1c monitoring, documentation of counselling, and detection of steroid-induced hyperglycaemia. Methods Data were gathered from the electronic medical records. Steroid-induced hyperglycaemia was defined as new HbA1c &amp;gt;48 measured 3+ months after beginning steroid treatment. The data were presented at a regional meeting to raise awareness and encourage clinicians to incorporate counselling and monitoring into their practice, and a GCA clinic was set up. Practice was then re-evaluated. Results In the baseline dataset, 60 patients with GCA had a mean age of 72; 47 were female; mean body mass index (BMI) was 27 (for the 39/60 with a recorded height and weight). Mean initial dose of prednisolone was 45.9mg. The re-audit cohort were comparable with a mean age of 73.1; 19 females and mean BMI of 27 (for 15/30 with recorded). Mean initial prednisolone dose of 46.3mg. Baseline HbA1c was checked in 32/60 (53%) initially, and 28/30 (93%) on re-audit. 7/60 (12%) had documentation of counselling for steroid-induced hyperglycaemia initially, which increased to 9/30 (30%) on re-audit. Hyperglycaemia was detected in 8/60 (13%) of the initial audit group, compared to 11/30 (36%) in the re-audit. In the initial cohort, 3/10 (30%) of those with diabetes at baseline developed hyperglycaemia and 4/12 (33%) of those with pre-diabetes at baseline developed hyperglycaemia. In the re-audit, 7/9 (78%) of those with diabetes at baseline developed hyperglycaemia and 4/7 (57%) with pre-diabetes at baseline developed hyperglycaemia. Those who developed hyperglycaemia had a higher baseline weight and BMI (Table 1) in both the initial cohort and re-audit. Conclusion The intervention improved monitoring for steroid-induced hyperglycaemia, improving detection rates. We identified patient counselling as a priority for future improvement work. Disclosure L.J. Blackmore: None. K.L. Devine: None. S.L. Mackie: Consultancies; On behalf of University of Leeds for AbbVie, AstraZeneca, Sanofi, Roche. Other; Support from Roche to attend EULAR2019.

rheumatology

P026 Sugar rush: single-centre audit of screening and counselling for steroid-induced hyperglycaemia, based on the British Society for Rheumatology giant cell arteritis guideline